Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Over the last 7 days, the United States market has experienced a 2.5% ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to value ...

EXEL's 2025 total revenue guidance is flat at $2.15B-$2.25B, although that doesn't model potential approval of cabozantinib for neuroendocrine tumors. EXEL's STELLAR-303 trial of zanzalintinib in ...

Julie Smith, a director at $EXEL, sold 19,294 shares of the company on 02-28-2025 for an estimated $725,840. We received data on the trade from a recent SEC filing ...

$EXEL insiders have traded $EXEL stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.